These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 26082811)
1. Changes in Skeletal Tumor Activity on (18)F-choline PET/CT in Patients Receiving (223)Radium Radionuclide Therapy for Metastatic Prostate Cancer. Miyazaki KS; Kuang Y; Kwee SA Nucl Med Mol Imaging; 2015 Jun; 49(2):160-4. PubMed ID: 26082811 [TBL] [Abstract][Full Text] [Related]
2. Prognosis Related to Metastatic Burden Measured by ¹⁸F-Fluorocholine PET/CT in Castration-Resistant Prostate Cancer. Kwee SA; Lim J; Watanabe A; Kromer-Baker K; Coel MN J Nucl Med; 2014 Jun; 55(6):905-10. PubMed ID: 24676753 [TBL] [Abstract][Full Text] [Related]
3. Prediction of PSA Progression in Castration-Resistant Prostate Cancer Based on Treatment-Associated Change in Tumor Burden Quantified by 18F-Fluorocholine PET/CT. Lee J; Sato MM; Coel MN; Lee KH; Kwee SA J Nucl Med; 2016 Jul; 57(7):1058-64. PubMed ID: 26912444 [TBL] [Abstract][Full Text] [Related]
4. Fluorine-18-fluorocholine PET/CT parameters predictive for hematological toxicity to radium-223 therapy in castrate-resistant prostate cancer patients with bone metastases: a pilot study. Vija Racaru L; Sinigaglia M; Kanoun S; Ben Bouallègue F; Tal I; Brillouet S; Bauriaud-Mallet M; Zerdoud S; Dierickx L; Vallot D; Caselles O; Gabiache E; Pascal P; Courbon F Nucl Med Commun; 2018 Jul; 39(7):672-679. PubMed ID: 29790867 [TBL] [Abstract][Full Text] [Related]
5. Uptake of Radium-223 Dichloride and Early [ Letellier A; Johnson AC; Kit NH; Savigny JF; Batalla A; Parienti JJ; Aide N Mol Imaging Biol; 2018 Jun; 20(3):482-491. PubMed ID: 29027074 [TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of Filippi L; Spinelli GP; Chiaravalloti A; Schillaci O; Equitani F; Bagni O Biomedicines; 2020 Nov; 8(12):. PubMed ID: 33266047 [TBL] [Abstract][Full Text] [Related]
7. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Quaquarini E; D'Ambrosio D; Sottotetti F; Gallivanone F; Hodolic M; Baiardi P; Palumbo R; Vellani C; Canevari C; Bernardo A; Castiglioni I; Porta C; Trifirò G Contrast Media Mol Imaging; 2019; 2019():4325946. PubMed ID: 31049043 [TBL] [Abstract][Full Text] [Related]
9. Soft Tissue Response on 18F-Fluorocholine PET/CT in Metastatic Castrate-Resistant Prostate Cancer Treated With 223Ra-Dichloride: A Possible Abscopal Effect? Kwee SA; Lim J; Coel MN Clin Nucl Med; 2017 Nov; 42(11):868-871. PubMed ID: 28872544 [TBL] [Abstract][Full Text] [Related]
10. Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival. Etchebehere EC; Araujo JC; Fox PS; Swanston NM; Macapinlac HA; Rohren EM J Nucl Med; 2015 Aug; 56(8):1177-84. PubMed ID: 26069307 [TBL] [Abstract][Full Text] [Related]
11. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer. Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408 [TBL] [Abstract][Full Text] [Related]
12. Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer-Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT. Kairemo K; Joensuu T Diagnostics (Basel); 2015 Oct; 5(4):413-27. PubMed ID: 26854163 [TBL] [Abstract][Full Text] [Related]
13. Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety. Nilsson S Expert Opin Drug Saf; 2015 Jul; 14(7):1127-36. PubMed ID: 26022669 [TBL] [Abstract][Full Text] [Related]
14. Predictive and Prognostic Cruz-Montijano M; Amo-Salas M; Cassinello-Espinosa J; García-Carbonero I; Villa-Guzman JC; Garcia-Vicente AM Cancers (Basel); 2024 Jul; 16(15):. PubMed ID: 39123422 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of bone metastases by 18F-choline PET/CT in a patient with castration-resistant prostate cancer treated with radium-223. Scalzi P; Baiocco C; Genovese S; Trevisan A; Sirotova Z; Poti C Urologia; 2017 Feb; 84(1):61-64. PubMed ID: 27911459 [TBL] [Abstract][Full Text] [Related]
16. Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone. Takalkar A; Adams S; Subbiah V Exp Hematol Oncol; 2014; 3():23. PubMed ID: 25243101 [TBL] [Abstract][Full Text] [Related]
18. One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer. Jadvar H; Challa S; Quinn DI; Conti PS Cancer Biother Radiopharm; 2015 Jun; 30(5):195-9. PubMed ID: 25746633 [TBL] [Abstract][Full Text] [Related]
19. The safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer. Wilson JM; Parker C Expert Rev Anticancer Ther; 2016 Sep; 16(9):911-8. PubMed ID: 27501059 [TBL] [Abstract][Full Text] [Related]
20. Accurate Monitoring of the Response of Bone Metastases to Treatment in Patients with Prostate Cancer Using Choline PET/CT. Kitajima K; Yamamoto S; Fujiwara M; Kawanaka Y; Yamada Y; Nagasawa S; Shimatani K; Hanasaki T; Taguchi M; Kanematsu A; Yamakado K Case Rep Oncol; 2021; 14(1):520-524. PubMed ID: 33976628 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]